Scientific Programme
12:30
Welcome
Session: From basic science to clinical application
Chair: Jan B. Vermorken (BE)
13:00
Oral potentially malignant disorders (OPMD): an update
Ruud Brakenhoff (NL)
13:25
The role of artificial intelligence in OPMD
Pierre Saintigny (F)
13:50
Treatment of OPMD and first results of immune checkpoint inhibitors
Paolo Bossi (I)
14:15
Innovations in cell-based assays for drug discovery and drug evaluation
Ingeborg Tinhofer (DE)
14:40
Break and poster viewing
15:10
Is the ESCAT ranking of support in head and neck cancer management?
Maud Kamal (F)
15:35
Mechanism of action and potential use of SMAC mimetics in HNSCC
Ben O’Leary (UK)
16:00
Precision medicine beyond genomics
Enrique Sanz (CA)
16:25
Proffered paper session 1
chaired by René Leemans (NL)
19:00
Welcome reception
Session Primary disease (1)
Chair Hans Langendijk (NL)
08:30
Sentinel Node Biopsy in cN0 Early-Stage Oral Cavity Cancer: what is the evidence?
Clare Schilling (UK)
08:55
Partial laryngeal surgery in 2023
Giovanni Succo (I)
09:20
Managing the internal carotid artery in head and neck cancer: where are we?
Piero Nicolai (I)
09:45
Improving quality of reconstructive surgery in head and neck cancer
Sat Parmar (UK)
10:10
Coffee break and poster viewing
10:45
Innovation in radiotherapy: “FLASH-therapy”
Jean Bourhis (CH)
11:10
Hypoxia in head and neck cancer: current relevance
Olivier Feron (BE)
11:35
Hyperthermia: a game changer in the management of head and neck cancer?
Anthony Kong (UK)
13:30
Lunch and poster viewing
Session Primary disease (2)
Chair: Piero Nicolai (I)
14:30
Prognostic factors in HPV-positive oropharyngeal cancer: an update
Brian O’Sullivan (CA)
14:55
Immunotherapy and novel agents in locoregionally advanced HNSCC
Jean-Pascal Machiels (BE)
15:20
Is reducing the extent of local treatments justified after successful neoadjuvant therapy?
Andreas Dietz (DE)
15:45
Noninvasive biomarkers predicting outcome in patients with locoregionally advanced HNSCC
Ricard Mesia (ES)
16:10
Coffee break
16:40
Innovations in head and neck surgery in the 21st century
René Leemans (NL)
17:05
Impact of emerging technology developments in proton therapy
Hans Langendijk (NL)
17:30
Proffered paper session
chaired by Jean-Pascal Machiels (BE)
18:30
Debate
moderator Jan Vermorken (BE)
This house believes that hypoxic modification should be used to enhance the effect of
(chemo)radiation in patients with locoregionally advanced HNSCC
Pro-position: Jens Overgaard (seconded by Jean Bourhis (CH))
Contra-position: Vincent Gregoire (seconded by Hans Langendijk (NL))
Session Recurrent/Metastatic (R/M) disease
Chair: Brian O’Sullivan (CA)
08:30
50 years of systemic therapy: what have we gained?
Jan Vermorken (BE)
08:55
The potential roles of Antibody-Drug Conjugates in head and neck cancer
Christophe Le Tourneau (F)
09:20
Intratumoral drug administration: more potential in head and neck cancer?
Kevin Harrington (UK)
Sponsored lecture (Nanobiotix)
09:45
Novel radioenhancer NBTXR3 as a single agent in locally advanced (LA) HNSCC or in combination with anti-PD1 in R/M HNSCC
Jean Bourhis (CH)
10:10
Coffee break
10:45
Metronomic chemotherapy and immunotherapy: a fascinating approach
Kumar Prabhash (IN)
11:10
Metastatic head and neck cancer: what is the optimal local treatment?
Petr Szturz (CH)
Session Salivary Gland cancer
11:35
Molecular characterization of salivary gland cancer and treatment implications
Alberto Hernando (ES)
12:00
Salivary duct carcinoma: strategies to improve outcome
Lisa Licitra (I)
12:25
General discussion
13:00
Adjourn